The partnership aims to drive the industry in the areas of personalized medicine, monoclonal antibodies, and gene and cell therapies. Part of the agreement includes implementing Thermo Fisher's Orbitrap Exploris 240 mass spectrometer and Vanquish Duo ultra-high performance liquid chromatography (UHPLC) system within Northeastern's Biopharmaceutical Analysis Training Laboratory.

The equipment will help analyze the complex molecules defining the medicines of the future and will help those in the lab develop chromatography-based workflows for the streamlined analysis of biotherapeutics.

Thermo Fisher expands collaboration with Symphogen
Thermo Fisher Scientific has expanded its collaboration with Symphogen to support that company's efforts to provide therapeutic proteins for biopharmaceutical...

Thermo Fisher expands Direct-to-Patient clinical trial service
Thermo Fisher Scientific said it has expanded its Direct-to-Patient clinical trial service to enable clinical trial medications to be delivered directly...

Thermo Fisher's Q3 earnings boosted by COVID-19 sales
Products related to the novel coronavirus are spelling success for Thermo Fisher, which reported that revenue was up by 36% in the third quarter to $8.52 billion,...

Thermo Fisher launches closed cell processing system
Thermo Fisher Scientific has launched the Gibco CTS Rotea counterflow centrifugation system, a modular, closed cell therapy processing system for cell...

Thermo Fisher to add sterile filling lines in Singapore
Thermo Fisher Scientific will operate a $130 million facility in Singapore that will be used to develop two new sterile filling lines, extending...